Fas/APO-1 is a transmembrane protein of the nerve growth factor/TNFa receptor family which signals apoptotic cell death in susceptible target cells. We have investigated the susceptibility of seven human malignant glioma cell lines to Fas/APO-1-dependent apoptosis. Sensitivity to Fas/APO-1 antibody-mediated cell killing correlated with cell surface expression of Fas/APO-1. Expression of Fas/APO-1 as well as Fas/APO-1-dependent cytotoxicity were augmented by preexposure of human malignant glioma cells to IFNy and TNFa. Further, pretreatment with TGFp2, IL1 and IL8 enhanced Fas/APO-1 antibody-induced glioma cell apoptosis whereas other cytokines including TNFfi, IL6, macrophage colony-stimulating factor, IL10 and EL13 had no such effect. None of the human malignant glioma cell lines was susceptible to TNFa-induced cytotoxicity. Fas/ APO-1 antibody-sensitive glioma cell lines (n = 5), but not Fas/APO-1 antibody-resistant glioma cell lines (n = 2), became sensitive to TNFa when co-treated with inhibitors of RNA and protein synthesis. Resistance of human glioma cells to Fas/APO-1 antibody-mediated apoptosis was mainly related to low level expression of Fas/APO-1 and appeared not to be linked to overexpression of the antiapoptotic protooncogene, bcl-2. Given the resistance of human malignant glioma to surgery, irradiation, chemotherapy and immunotherapy, we propose that Fas/APO-1 may be a promising target for a novel locoregionary approach to human malignant glioma. This strategy gains support from the demonstration of Fas/APO-1 expression in ex vivo human malignant glioma specimens and from the absence of Fas/APO-1 in normal human brain parenchyma. (J. Clin. Invest. 1994. 94:954-964.)
Introduction
The prognosis for malignant glioma patients has not been significantly improved for many years. The infiltrative growth pattern of these neoplasms precludes curative neurosurgery and glioma cells fail to respond to irradiation, chemotherapy or immunotherapy (1) . It has increasingly been recognized in recent years that malignancy may not exclusively result from enhanced cell proliferation but also from decreased physiological cell death, apoptosis. This was most conclusively demonstrated by the identification of the proto-oncogene, bcl-2, which upon deregulated expression in follicular lymphoma confers oncogenicity by rendering cells resistant to the endogenous death program of apoptosis (2) . Apoptosis is a physiological form of cell death often referred to as "programmed" since apoptosis is a pathway of developmental cell elimination, e.g., in the immune and nervous system which allows for the safe disposal of cellular remnants without causing harm to surrounding tissue (3) (4) (5) (6) . This is accomplished by fragmentation of nucleus and cytoplasm into membrane-coated apoptotic bodies which are rapidly cleared from an organism by neighboring cells acting as nonprofessional phagocytes. Exposure to many chemotherapeutic drugs as well as irradiation activate the apoptotic death program in susceptible target cells (7, 8) . Overexpression of bcl-2 has been shown to inhibit not only apoptosis induced by growth factor deprivation but also apoptosis induced therapeutically by chemotherapy and irradiation (9) . Novel therapeutic approaches must thus target tumor cells which have developed effective means to escape negative growth regulators and apoptosis-inducing signals.
The identification of Fas/APO-l (CD 95) (10, 11) , atransmembrane receptor protein belonging to the nerve growth factor/TNFa receptor family (12-15), led to the detection of a unique endogenous apoptotic death program which may play a significant role in the development of the immune system (16, 17) , in cytotoxic T cell-mediated killing (18) and in malignant transformation (19) . Ligation of Fas/APO-l has been proven effective in experimental immunotherapy studies of human B lymphoblastoid tumors in nude and SCID mice (11, 20) . The endogenous Fas/APO-1 ligand has recently been identified as a novel member of the TNF family expressed at the cell surface and shed into the cell culture supernatant (21, 22) .
We have previously examined nontransformed astrocytes and malignant glioma cells in regard to the synthesis and release of immunosuppressive and proinflammatory cytokines and their possible role as antigen-presenting cells in the central nervous system (23) (24) (25) (26) (27) de Tribolet (Lausanne, Switzerland) were maintained in DME (HyClone, Cramlington, UK) containing 10% FCS, 2 mM N-acetyl-Lalanyl-L-glutamine (Seromed, Berlin, Germany) and 10 Mg/ml gentamycin (GIBCO, Paisley, Scotland) as described (25) (26) (27) . In most experiments the cells were preactivated by cytokines at subconfluency in DME containing 10% FCS for 24 h and then switched to DME/0.5% FCS for Fas ab or TNFa exposure or modulations thereof for 2-48 h. TNFa release by glioma cells was examined by bioassay using L-M murine fibroblasts (28) . The glioma cell lines were mycoplasma-free as assessed by ELISA (Boehringer Mannheim).
Detection of Fas/APO-I expression. For flow cytometric analysis of Fas/APO-l expression, glioma cells were scraped off the culture dishes and washed in HBSS. 106 cells were resuspended in a volume of 150 p1 flow cytometry buffer containing PBS, pH 7.4, 1% FCS, and 0.01% sodium azide. The samples were incubated with FITC-conjugated Fas monoclonal ab UB2 (1 pg/ml) at 4°C for 1 h and washed twice in flow cytometry buffer. A total of 10,000 viable cells were analysed on an Epics profile analyzer. The percentage of positive cells was calculated directly from the gated histograms.
Soluble protein for Western blotting was harvested from cells lysed for 15 min on ice in 50 mM Tris-HCl, pH 8, containing 120 mM NaCl, 0.5% NP-40, 2 pg/ml aprotinin, 100 Mg/ml PMSF, 10 Mg/ml leupeptin, 50 mM sodium fluoride, and 200 pM sodium vanadate followed by high-speed centrifugation at 4°C. 20 pg protein per lane were separated by 12.5% SDS PAGE and electroblotted to nitrocellulose. Immunodetection involved blocking for I h in 10 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 0.1% Tween 20, 5% skim milk and 2% BSA, incubation with Fas ab CH-I1 (5 ,g/ml) overnight at 4°C, incubation with biotinylated anti-mouse IgM (1:10,000 in PBS/0.1% Tween 20), streptavidinalkaline phosphatase ( 1:1,000) and nitroblue tetrazolium chloride (0.41 mM) and 5-bromo-4-chloro-3-indolyl phosphate (0.38 mM) in 200 mM Tris-HCl, pH 9.5, containing 10 mM MgCl2 as substrate. Bcl-2 expression was detected according to the same protocol except that the first ab was anti-human bcl-2 and the second ab was biotinylated antimouse IgG.
Assessment ofFas ab-mediated cytotoxicity and apoptosis. Cell proliferation and viability were determined by crystal violet staining and trypan blue dye exclusion. Morphological changes induced by Fas ab were closely monitored by phase contrast microscopy and toxicity rated independently by two of us (M. Weller and K. Frei) as no toxicity (-), mild toxicity ( + ), severe toxicity ( + + ), or complete dissolution of the monolayer ( + + + ). This rating scale was specifically required to assess the effects of cytokines on Fas ab-mediated toxicity which induced both glioma cell proliferation and sensitization to Fas/APO-l-mediated glioma cell apoptosis. Apoptotic cell death was monitored using phase contrast microscopy and acridine orange nuclear staining. DNA fragmentation was examined by quantitative Hoechst 33258 fluorometry, by in situ DNA end labeling and by DNA agarose gel electrophoresis as previously outlined (29) . In situ DNA end labeling (30) was performed using terminal transferase (0.25 U/ml)-mediated incorporation of biotinylated deoxyuridine triphosphate (50 pM) and streptavidinalkaline phosphatase detection as described above for Western blotting. For in situ DNA end labeling and acridine orange nuclear staining, 104 glioma cells were grown for 72 h on poly-L-lysine (0.01%)-coated eight-well Labtek chamber glass slides (Nunc, Roskilde, Denmark), treated as indicated and fixed for 5 min in 4% formaldehyde in PBS. Glioma cells which detached from the monolayer were harvested from the medium by low speed centrifugation, resuspended in 4% formaldehyde/PBS and fixed on poly-L-lysine-coated glass slides for staining. Acridine orange (1 pg/ml) in PBS containing 100 pg/ml RNAse A was applied to the specimens for 20 min at room temperature, followed by two washes in PBS and air-drying.
For quantitative DNA fluorometry, 106 cells per ml were lysed in 10 mM Tris-HCl, pH 7.5, 10 mM EDTA and 0.2% Triton X-100 for 10 min on ice. Fragmented DNA was separated from nucleus-attached DNA by high-speed centrifugation. After disruption of the pellets by brief sonication and RNAse A digestion, fragmented and pelleted DNA were measured by Hoechst 33258 (1 pg/ml) fluorometry using 360 nm excitation and 460 nm emission wave lengths (CytoFluor 2350; Millipore Corp., Bedford, MA). The linear range was between 0.05 and 3 pg/ml DNA. This assay was performed differentially on cells which had detached from the monolayer and on intact monolayer cells. Percentage fragmentation was calculated by dividing fragmented DNA by the total sum of fragmented and pelleted DNA.
For the demonstration of nucleosomal size DNA fragmentation, glioma cells were lysed as described above for quantitative fluorometry. Nonpelleted DNA was harvested from the supernatants of the cell lysates by phenol dichloromethane extraction and sodium acetate/ethanol precipitation. DNA agarose gel electrophoresis was performed on 1.5% gels in 10 mM Tris-HCl, pH 8, containing 1 mM EDTA and 1 Mg/ml ethidium bromide.
For transmission electron microscopy glioma cells treated as indicated were fixed for 30 min at 4°C in 0.05 M cacodylate buffer containing 2% glutaraldehyde and 0.8% paraformaldehyde, postfixed in 0.1 M cacodylate buffer containing 1% Os04 and 1.5% K4(FeCN)6 and embedded into epon. Adherent monolayer cells were scraped off the dish for fixation, detached cells were collected from the supernatants by low speed centrifugation. Ultrathin sections contrasted with uranyl acetate and lead citrate were examined with a Philips TEM 420 transmission electron microscope.
Immunocytochemical detection of Fas/APO-I expression in human ex vivo glioma tissue. Cryopreserved human glioma sections were fixed in acetone for 5 min at -20°C, air-dried and blocked for 20 min with PBS containing 10% goat serum. The specimens were exposed to mouse anti-human APO-1 ab (11) or anti-human Fas ab UB2 (1 Mg/ml) diluted in PBS containing 2% goat serum and 10% human serum for 2 h, washed extensively in PBS and subsequently incubated with peroxidaseconjugated anti-mouse IgG diluted 1:100 in PBS containing 2% goat serum and 10% human serum. Diaminobenzidene was used as a substrate and Mayer's hematoxylin as counterstain. To confirm specificity of Fas/APO-1 detection, parallel sections were treated with non-immune mouse IgG instead of APO-1 or UB2 ab. To confirm a glial origin of Fas/APO-1-positive cells, parallel sections were reacted with rabbit anti-glial fibrillary acidic protein ab and alkaline phosphatase-labeled anti-mouse IgG using nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate as substrate as described above.
Statistical analysis. EC50 values were determined by linear regression analysis. Effects of simple treatments were compared by student's t test. Composite treatments were compared by ANOVA.
Results
Expression of Fas/APO-I in human malignant glioma cells and its modulation by IFNy and TNFa. We initiated our study (Fig. 1 ) but also the mean fluorescence (data not shown) in all glioma cell lines except LN-308. When the data from the independent experiments were pooled and constitutive expression of Fas/APO-I by the glioma cells compared with Fas/ APO-1 expression following exposure to IFNy, TNFa, or both cytokines, the combination of both cytokines failed to enhance Fas/APO-l expression significantly over expression induced by the more potent cytokine alone in any individual cell line (ANOVA). Expression of Fas/APO-1 was confirmed by Western blotting using the monoclonal IgM Fas ab (10) which recognized a protein of 43 kD in all seven glioma cell lines (data not shown).
Human malignant glioma cells are susceptible to cytokinemodulated Fas/APO-l-mediated cytotoxicity. Cytotoxicity assays performed on seven human malignant glioma cell lines cultured for 24 h with or without Fas monoclonal ab CH-11 ( 1 /Lg/ml) (10) increased until 24 h after exposure. Fas/APO-l ab-mediated cytotoxicity was apoptotic rather than necrotic by phase contrast microscopy, acridine orange nuclear staining, in situ DNA end labeling (Fig. 3, a and b) , transmission electron microscopy ( Fig. 3, c-f ) , quantitative DNA fragmentation analysis (Fig.  4 a) and DNA agarose gel electrophoresis (Fig. 4 b) . After exposure of sensitive cell lines to Fas ab, in situ DNA end labeling allowed the detection of DNA breaks in virtually all glioma cells recovered from the medium and in a minor proportion of adherent cells (< 10%) (Fig. 3, a and b) . These observations were corroborated by quantitative DNA fragmentation data obtained using Hoechst 33258 fluorometry (Fig. 4 a) . This technique enabled us to confirm that DNA breaks were induced by Fas ab exposure early in the course of apoptosis and preceded cell detachment from the monolayer because a significant increase of DNA fragmentation following Fas ab exposure was detected in DNA extracted not only from detached cells but also from adherent monolayer cells. Note that the relative degree of DNA fragmentation in a cell population uniformly undergoing apoptosis depends on the cell type studied and may not exceed 20-30% because the majority of genomic DNA remains associated with the apoptotic nuclei and is pelleted upon centrifugation (31, 32 (Fig. 4 b) . Transmission electron microscopy of Fas ab-sensitive glioma cells exhibited typical ultrastructural features of apoptosis (Fig. 3, c and d) . Early apoptotic stages were characterized by condensation of heterochromatin in the absence of damage to cell organelles (Fig. 3 d) . More advanced stages of apoptosis showed disruption of the nuclear envelope and swelling of cell organelles notably endoplasmatic reticulum (Fig. 3 e) . Apoptosis was completed by expulsion of heterochromatin, by fragmentation of heterochromatin and cytoplasm into apoptotic bodies and by complete dissolution of the cytoplasm (Fig. 3 f ) .
Correlation between Fas ab sensitivity and sensitivity to TNFa in the presence of RNA and protein synthesis inhibitors. Sensitivity to Fas ab has been linked to TNFa cytotoxicity (10) and there are homologies between the receptors, Fas/APO-1 and the TNFa receptor (14, 15) and between the respective ligands, the Fas/APO-1 ligand and TNFa (21) . The initial characterization of Fas ab-mediated cytotoxicity of human glioma cells (Fig. 1 ) Correlation between bcl-2 expression and Fas/APO-I sensitivity. Overexpression of antiapoptotic genes may be an important escape mechanism of tumor cells from cytotoxic stimuli.
We therefore examined whether resistance to Fas/APO-l-mediated apoptosis was associated with enhanced bcl-2 expression (Fig. 5) . LN-229 and LN-308 showed the highest levels of bcl- 2 Fas ab was used at 1 tzg/ml, TNFa at 10 ng/ml, ActD at 0.1 gg/ml, and CHX at 1 4g/ml in DME/0.5% FCS. Data are expressed as percent survival of untreated controls for cultures exposed to Fas ab or TNFa alone or as percent survival of cultures exposed to the respective concentrations of ActD or CHX alone. Cytotoxicity induced by ActD or CHX alone did not exceed 30%. Cell loss was assessed at 24 h by crystal violet staining (n = 3, * P < 0.03, t P < 0.01 by ANOVA).
(19) but there are no data on Fas/APO-1 expression on human brain tumors. To assess whether Fas/APO-1 expression was restricted to long-term cultured human glioma cell lines or also detectable on human malignant glioma cells in vivo, we studied Fas/APO-l expression in ex vivo human glioma specimens. Of 7 gliomas examined, three showed extensive Fas/APO-l immunoreactivity, two showed moderate immunoreactivity, and two were negative (Fig. 6) . Immunoreactivity was fairly homogenous within the single neoplasms and most pronounced at cell borders, as predicted for a membrane-associated protein.
The tissue sections were taken from the center of the neoplasms to avoid confusion of tumor cells with infiltrating host cells. A glial origin of Fas/APO-1 immunoreactivity was confirmed by positive staining for glial fibrillary acidic protein in all cases.
A normal human brain autopsy specimen showed occasional Fas/APO-l immunoreactivity on endothelial cells but brain parenchyma was negative ( 19) . The expression of Fas/APO-1 by human malignant glioma cells in vivo was also assessed by Western blot analysis of freshly isolated human tumor cells (Fig. 7) . The monoclonal IgM Fas ab recognized a band of 43 kD corresponding to Fas/APO-l in 6 of 8 high-grade malignant glioma specimens.
Discussion
The failure of human malignant glioma to respond to current treatment protocols requires the evaluation of novel treatment strategies. This study shows that malignant glioma cells express The cytokines were added to the cultures for 24 h in DME/10% FCS at the concentrations indicated. The cells were washed and then exposed to Fas ab (1 ,ug/ml; 0.1 og/ml for LN-18) in DME/0.5% FCS for 24 (10, 36, 46) . Induction of Fas/APO-l cell surface expression by IFNy and TNFa has been described (10, 19, 37, 47) . Our data suggest that cytokine-mediated upregulation of Fas/APO-l expression may not be the only mechanism of cytokine-mediated sensitization of human glioma cells to Fas abmediated cytotoxicity since IFNy enhanced Fas/APO-l expression of LN-319 or T98G cells in the absence of augmentation of killing and since TNFa induced killing of LN-319 cells in the absence of enhanced Fas/APO-l expression (Fig. 1) . A combination of cytokines may be most efficient in enhancing both Fas/APO-1 expression and susceptibility to Fas ab-mediated killing. Resistance to Fas/APO-1 ab despite cell surface expression of the antigen as seen in IFNy/TNFa-treated LN-405 cells (Fig. 1) is not a unique feature of malignant glioma cells but has been described in resting and activated human 29 18 9 ; -?. (Fig. 5) . Abrogation of Fas ab-mediated apoptosis by enforced bcl-2 expression has been reported in murine IL3-dependent FDC-P1 cells and WR19L lymphoma cells (54) . A possible association of decreased bcl-2 mRNA with enhanced susceptibility to APO-1 ab was detected in human B cell leukemias (51) . Anti-oxidant properties of bcl-2 (55) and the putative role of oxygen free radicals in TNFamediated killing (34, 35, 53) further suggested that bcl-2 overexpression might induce resistance to Fas/APO-l-mediated apoptosis in specific cell types.
The apparent lack of correlation between Fas/APO-l ab sensitivity and bcl-2 expression in human malignant glioma cell lines (Fig. 5) is consistent with the failure of bcl-2 to prevent TNFa cytotoxicity (56) and killing by cytotoxic T cells (57) which may involve Fas/APO-l expression on target cells ( 18) . Further studies are needed to clarify a possible role of bcl-2 expression in the resistance of malignant glioma cells to Fas/ APO-1-dependent apoptosis. Bc1-2 expression in malignant glioma in vivo may be indicative of malignant transformation, possibly contributing to radioresistance, since normal astrocytes do not express bcl-2 in vivo (58) .
Immunotherapy of human malignant glioma targeting Fas/ APO-l in vivo requires the presence or inducibility of Fas/ APO-1 not only in malignant glioma cell lines but also in malignant gliomas in vivo and the absence of Fas/APO-l on nontransformed neurons and astrocytes or the failure of these cells to activate the endogenous death program of apoptosis in response to agonistic Fas/APO-I ab. Cloning of Fas/APO-1 (12, 13) and its ligand (21, 22) has allowed to study their expression in vivo. Fas/APO-I mRNA was detected in mouse thymus, liver, ovary and heart but not in brain (37). These data correspond to the absence of Fas/APO-l protein in brain in immunohistological studies of normal adult human tissue. Neither neurons nor astrocytes, oligodendrocytes, microglial or ependymal cells displayed immunoreactive Fas/APO-l protein although 50% of central nervous system endothelial cells were positive (19) . Fas/APO-1 protein was detected in numerous other cell types including hepatocytes, subpopulations of keratinocytes, lymphocytes, or intestinal tract epithelial cells. Fas ligand mRNA is expressed in rat splenocytes, testis, lung, kidney, and small intestine but again not in brain (21) . The absence of Fas/APO-l in normal brain parenchyma is the first prerequisite of Fas/APO-l targeting immunotherapy for malignant glioma, this is prevention of widespread tissue damage in normal brain. While this precondition appears to be met (19) , it remains to be investigated whether reactive astrocytes around the tumor tissue are Fas/APO-1-positive or would become so upon pre-or co-treatment with exogenous cytokines. The expression of Fas/APO-1 not only on cultured glioma cells but also on ex vivo human glioma specimens is the second precondition for Fas/APO-1 targeting to become a therapeutic approach to malignant glioma. Our data (Fig. 6) show that expression of Fas/APO-1 expression is not a consequence of long-term glioma cell culturing but is also detectable in vivo. Further experimentation is required to assess Fas/APO-1 expression in an extended sample of brain tumor specimens and to evaluate susceptibility to Fas ab-mediated cytotoxicity of fresh human glioma tissue. Locoregionary approaches via Ommaya reservoir and cerebrospinal fluid or via carotid and vertebral arteries have previously been employed to deliver lymphokine-activated killer cells or systemically toxic agents like immunoconjugates or TNFa to brain tumors ( 1, 59, 60) . Since systemic application of Fas ab in mice resulted in death from acute liver failure (61), Fas/APO-1 -targeting immunotherapy of malignant glioma will similarly have to be studied as a locoregionary approach unless pharmacological strategies to prevent systemic toxicity and to assure sufficient access to glioma tissue upon systemic application can be devised. The results of this study and the characteristics feature of malignant glioma not to spread outside the central nervous system suggest that these neoplasms are a putative target for Fas/APO-1-targeting oncological immunotherapy.
